OBJECTIVES To synthesize and analyze the available information on the burden of chronic urticaria (CU) [Patients’ Reported Outcomes (PROs): Health related quality of life (HRQoL), adherence, satisfaction, preferences, use of medical resources and costs] in Europe. METHODS A systematic review on PROs and costs of CU was performed. International (Pub Med, WOK, Scopus, Cochrane Library) and national (CSIC-IME, IBECS, MEDES) databases were consulted. Original articles, narrative/systematic reviews of studies developed in Europe, until December 2013 were retrieved. Editorials, letters/commentaries, and efficacy or economic evaluations of specific drugs were excluded. Costs were updated to €, 2013. RESULTS oL instrument, (0-100, higher value, worse HRQoL), was the most frequently used (n=4). Scores ranged from 18.4 (Greece) to 42.8 (Germany) revealing an acceptable perception of HRQoL. Sleep, itching/embarrassment and mental health were the HRQoL dimensions most impaired. Patients taking prescription drugs were more satisfied than those taking over the counter (p<0.01). Severely ill patients were willing to change therapies if new, more effective alternatives became available (p<0.05). Only 1 study assessed the costs of CU in Europe while another one described the use of medical resources. CU total cost in France was €2,139.48 per patient/year. Patients lost 2.2 working days/month, being productivity losses 92% of total costs. CU patients were mostly cared for a dermatologist according to findings in Germany. A mean of 11.7 (SD: 11.5) visits/month to the dermatology clinic were reported. CONCLUSIONS PROs and costs in CU are infrequently addressed in the literature. Findings show patients reduced HRQoL and their willingness for more effective therapies. Frequent medical visits and loss of productivity make CU a burdensome disease in European countries.